
-
Sangamo Therapeutics NasdaqCM:SGMO Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Location: 501 Canal Blvd, Richmond, CA, 94804, United States | Website: https://www.sangamo.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
106.4M
Cash
25.18M
Avg Qtr Burn
-11.16M
Short % of Float
14.05%
Insider Ownership
2.80%
Institutional Own.
22.35%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Giroctocogene fitelparvovec (SB-525 / PF-07055480) Details Rare diseases, Hemophilia, Rare genetic disease, Blood disorder | Phase 3 Update | |
ST-920 (isaralgagene civaparvovec) Details Fabry disease | Phase 1/2 Data readout | |
TX-200 Details Kidney disease, Kidney transplantation | Phase 1/2 Update | |
ST-503 Details Idiopathic small fiber neuropathy | Phase 1/2 Initiation | |
ST-506 Details Prion disease | IND Submission | |
ST-400 Details Blood disorder, Beta thalessemia | Failed Discontinued | |
SB-913 Details Genetic disorder, Rare diseases, Mucopolysaccharidoses, Rare genetic disease, Mucopolysaccharidosis type II | Failed Discontinued | |
BIVV003 (SAR445136) Details Sickle cell disease, Blood disorder | Failed Discontinued |